Back to results
US 2021/0275447 A1Published application
Sustained-release ophthalmic pharmaceutical compositions and uses thereof
OwnerKeelung HONG, Hao-Wen KAO +2inventors
InventorsKeelung HONG, Hao-Wen KAO, Yi-Yu LIN, Weiwei FANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to an ophthalmic pharmaceutical composition comprising at least one liposome and a therapeutic agent for treating an eye disease with a high drug to lipid ratio and encapsulation efficiency. Also provided is the method for treating age-related macular degeneration or diabetic eye disease using the ophthalmic pharmaceutical composition disclosed herein.
Claims18
A sustained release ophthalmic pharmaceutical composition, comprising
- (a) at least one liposome comprising a bilayer membrane, said bilayer membrane comprises at least one lipid;
- (b) a trapping agent;
- and
- (c) a therapeutic agent for treating an eye disease, wherein the molar ratio of the therapeutic agent to the lipid is equal to or higher than 0.2.
1 more element
A method for treating an eye disease, comprising:
- administering a sustained release ophthalmic pharmaceutical composition to a subject in need thereof, said ophthalmic pharmaceutical composition comprising:
- (a) at least one liposome comprising a bilayer membrane, said bilayer membrane comprises at least one lipid;
- (b) a trapping agent;
- and
- (c) a therapeutic agent for treating an eye disease, wherein the molar ratio of the therapeutic agent to the lipid is equal to or higher than 0.2.
2 more elements
Dependencies are inferred from the claim text.